Investor Ideas #Potcasts
555, #Cannabis News and #Stocks on the Move; (CSE: $XTRX.C) (TSX: $FAF.TO)
(CSE: $AION.C) (CSE: $IPOT.C) (OTC: $ISCNF) (TSX: $WEED.TO) (NASDAQ: $CGC)
Delta, Kelowna, BC, April 21, 2021 (Investorideas.com Newswire) www.Investorideas.com,
a global news source covering leading sectors including marijuana and hemp
stocks and its potcast site, www.potcasts.ca release today’s podcast edition of cannabis news and stocks to watch plus insight
from thought leaders and experts.
Listen to the podcast:
https://www.investorideas.com/Audio/Podcasts/2021/042121-StocksToWatch.mp3
Read this in full
at https://www.investorideas.com/news/2021/cannabis-potcasts/04211XTRX-FAF-AION-IPOT-ISCNF-WEED-CGC.asp
Hear Investor ideas cannabis potcast on iTunes
Hear the investor ideas potcast on Spotify
Today’s podcast overview/transcript:
Good
afternoon and welcome to another episode of Investorideas.com "Potcast"
featuring cannabis news, stocks to watch as well as insights from thought
leaders and experts.
Today’s podcast is sponsored by Phyto Extractions Inc. (CSE:XTRX), an agricultural-scale cannabis extraction, distillation and product manufacturer located in Langley, BC at its co-located Health Canada Licensed Standard Processing (extraction, no cultivation), Sales (extracts, topicals, and edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D license amendment.
In
today’s podcast we look at a few private and public company announcements.
Fire
& Flower Holdings Corp. (TSX:
FAF)
(OTCQX:
FFLWF) and its indirect wholly-owned subsidiary Hifyre Inc.,
today announced the milestone achievement of 250,000 Spark
PerksTM members across the Fire & Flower retail network.
Spark Perks members receive special
benefits where permitted, including: Spark Fastlane TM click-and-collect
checkout, personalized recommendations, curbside pickup, free rapid delivery,
and exclusive deals. No cannabis purchase is required to join the free program.
The Sparks Perks program is now
available across all Fire & Flower banners including Friendly Stranger,
Happy Dayz and Hotbox and delivers personalized product recommendations to
members.
"A core metric in our business
is lifetime customer value and the cost of customer acquisition. We believe
Spark Perks customers have the highest lifetime customer value in the industry
through their larger basket sizes, more frequent visits and the diversity of
products they consume," said Trevor Fencott, Chief Executive Officer of
Fire & Flower.
"While growing rapidly, we have
also focused on a low cost of customer acquisition. Although metrics such as
same store sales are important, as an evolved technology-enabled retail company
we focus on customer engagement metrics that will be critical as our platform
scales to the U.S."
Key
Metrics from the Spark Perks Program:
● Members
who order from Same Day Rapid Delivery spend 110 per cent more than non-members
and have 90 per cent larger baskets than non-members
● Members
served through Fastlane pickup spend 49 per cent more than non-members in-store
● Members
transacting in-store have 27 per cent larger basket sizes than non-members with
19 per cent more items in their baskets
The
Spark Perks program leverages the HifyreTM advanced digital retail and
analytics platform. Hifyre is the leading Canadian data and analytics platform
within the cannabis industry and recently entered into a strategic agreement
with BDS Analytics Inc. ("BDSA") to incorporate Hifyre's Canadian
digital retail and analytics into BDSA's existing online U.S.-based market
research platform. As part of the agreement, BDSA will offer Hifyre IQ Canadian
cannabis data to its U.S.-based clients and Hifyre will be able to provide U.S.
data from BDSA to its Canadian clients, allowing both companies to offer
enhanced, cross-border data to their respective consumer bases.
The
company also
announced that it will release its financial and operational
results for fourth quarter and the fiscal year of 2020 ended January 30, 2021
before financial markets open on April 27, 2021. The results will be available
on SEDAR and on the Company's website at https://fireandflower.com/investor-relations.
Following
the release of the results, Fire & Flower will host a conference call with
Trevor Fencott, President and Chief Executive Officer, and Nadia Vattovaz,
Executive Vice President, Operations and Chief Financial Officer at 8:30 a.m.
EDT on April 27, 2021. The conference call will discuss Fire & Flower's
fourth quarter and fiscal year 2020 financial and operational results and
updates on the Company's plans for fiscal year 2021.
Aion Therapeutic
Inc.
(CSE:
AION) announced
today that its proprietary and patented combinatorial
mushroom preparations AION F7 and AION F8 (collectively, the "Aion Mushroom Preparations" or
"Preparations") showed
high efficacy in killing HER2+ breast cancer cells, ER+/PR+ breast cancer
cells, and triple-negative breast cancer cells by direct cytotoxicity.
As
shown in recently completed third-party independent and carefully controlled
3D-spheroid cell culture studies performed at BIOENSIS laboratories, these
cytotoxicity studies demonstrated direct killing of the breast cancer cells by
the Aion Mushroom Preparations, which suggests such preparations may be
effective in treating HER2+ breast cancer, ER+/PR+ breast cancer, and the very
difficult to treat triple-negative breast cancer, with each of these types of
breast cancers tested independently.
In
separate independent studies at BIOENSIS laboratories using the
Antibody-Dependent Cellular Cytotoxicity (ADCC) assay and the
Antibody-Dependent Cellular Phagocytosis (ADCP) assay, the Aion Mushroom
Preparations also demonstrated enhanced cell killing of HER2+ breast cancer
cells via stimulation of the immune system. The Preparations showed similar
effectiveness as trastuzumab, a monoclonal antibody treatment sold under the
brand name Herceptin, manufactured by Roche and is a US FDA approved medication
useful for treating HER2+ breast cancer that is either early-stage or
advanced-stage/metastatic.
Herceptin
(trastuzumab) is the leading breast cancer drug with annual global sales of
around $7 billion.1 Other FDA approved biosimilar trastuzumab products include:
Trazimera (Pfizer), Kanjinti (Amgen), Ontruzant (Merck), Herzuma (Teva), and
Ogivri (Mylan). When Aion Mushroom Preparations were combined with Trastuzumab,
there was a greater than 60% increase in the killing of HER2+ breast cancer
cells when compared to Trastuzumab used alone.
Based
on these results, Dr. Herbert A. Fritsche, Chief Science Officer of Aion
Therapeutic and former Professor and Director of Clinical Chemistry at the
University of Texas, MD Anderson Cancer Center, stated, "The extremely
exciting results obtained from these independent 3D cell culture studies suggests
that when appropriate Aion Mushroom Preparations are used together, they may
offer a dual approach to the killing of HER2+ breast cancer cells through two
separate and distinct pathways (direct cytotoxicity and antibody dependent
cytotoxicity). The significant improvement in cancer cell cytotoxicity that was
observed when the Preparations were combined with Trastuzumab warrants
immediate further investigation in breast cancer patients." Dr. Fritsche
continued, "We look forward to the next step of initiating clinical trials
of the Aion Mushroom Preparations with and without Herceptin (and other
trastuzumab biosimilars) for the treatment of HER2+ breast cancer patients as
well as the Aion Mushroom Preparations alone in ER+/PR+ breast cancer and
triple-negative breast cancer patients."
"Each
year more than 1.6 million new cases of breast cancer are diagnosed globally,
making it the most common cancer among women, and more than 500,000 women will
die of the disease," said Graham Simmonds, Executive Vice Chair and CEO of
Aion Therapeutic. He added, "We are excited that these Aion Mushroom
Preparations that have shown very encouraging initial test results will be
developed to be transformative in how women are treated globally."
Isracann
Biosciences Inc. (CSE:
IPOT) (OTC:
ISCNF) an Israel-based company focused on becoming a premier
low cost, high quality cannabis producer/distributor announced that it
has been granted a Foreign Owners Cannabis License by the Israeli Minister of
Health. This important event paves the way to conclude a number of outstanding
key partnership and regulatory considerations in preparation for commercial
operations.
In
a press release issued on March 24, 2020, Isracann announced its entry into a
joint venture (JV) agreement as part of a phased partnership of two near-term
farm operations located in Ein Hahoresh, Israel. The agreement included an
equitable sharing arrangement of both operating costs and revenue through
participatory agreements comprising construction services, growing services,
land lease agreements, IMCA licenses, and a number of sub agreements
establishing and defining the various rights of all parties. Today’s
announcement represents the removal of regulatory ownership barriers in order
to fully execute the terms of the JV plan.
The
highly sought-after foreign owners license significantly legitimizes the
Company’s presence in Israel. There are only a small number of foreign owned
sector participants who have obtained similar licencing, and Isracann is now
favourably positioned to leverage certain advantages. Ownership licensing
allows for greater access to domestic partnerships, increased participation in
state-sponsored initiatives, and enhances access to financing. It also
simplifies the Company’s ability to undertake domestic acquisitions, including
the conclusion of its planned purchase of a third-party participant in the JV
which would result in Isracann increasing its ownership position to 50%.
In
related news, the Company has concluded all requisite construction and
infrastructural installations in preparation for the commencement of planting
and subsequent production at its Hefer Valley-based Ein Hahoresh Farm. Largely
due to COVID-19 related delays, Isracann has a final regulatory hurdle to
conclude which appears to be moving closer to conclusion. Based on discussions
with our regional consultants, we are waiting for an inspection by law
enforcement officials and concurrent Ministry of Health approvals. It is our
understanding that scheduling for the inspection is imminent. Upon receipt,
Isracann will have full approval to begin planting.
Regarding
the recently announced medical cannabis import partnership LOI, Isracann is
working diligently with the Israeli partner to conclude the agreement for the
importation of Canadian products on an expedited basis. Additionally, Isracann
is finalizing an agreement with its Canadian partners to secure high-grade
genetic material for introduction into its Israeli-based genomics program.
While regional strains have certain inherently excellent traits, Isracann aims
to broaden product diversity, and through expert agronomy to achieve a
selection of world-class offerings.
Isracann
CEO, Darryl Jones states, “We continue to push ahead on multiple fronts. From
product importation to new genetics programs on the one hand, today we also
celebrate our official approval as foreign owners in this exciting sector. Now
we can truly dig in to finalize matters and accelerate our efforts to fully
enter the commercial marketplace. We’ve been in communication with all the
relevant parties and now with the licensing in-place, a number of initiatives
will be triggered almost immediately and should result in an accelerated pace
towards revenue generation. We have to admit that we always thought the
pandemic would create a delay, and it could have been worse. In the meantime,
we have by no means been standing still and have used the opportunity to invest
in added value and develop our relations throughout the region. Once again we
thank our Israeli team of consultants and stakeholders who have proven to be
invaluable at representing our interests so effectively and who share our
vision for success.”
Canopy Growth
Corporation (TSX:
WEED) (NASDAQ:
CGC),
a world-leading diversified cannabis, CBD and vaporization device company, today
announced Southern Glazer's Wine & Spirits, the world's
pre-eminent distributor of beverage alcohol, as the distribution partner for
its U.S. portfolio of CBD-infused beverages. This partnership announcement
follows the recent launch of Quatreau – Canopy's first line of CBD-infused
beverages sold in the U.S market.
"Through
this groundbreaking partnership, we will leverage Southern Glazer's established
distribution network to bring our CBD beverage portfolio to retailers and
consumers across the U.S. market," said Julious Grant, Chief Commercial
Officer, Canopy Growth. "The leadership team at Southern Glazer's shares
our values, priorities, and future-forward view of the category. Together, we
are committed to creating an immediate strategic route to market for Canopy's
premium CBD beverages."
Southern
Glazer's will distribute Canopy Growth's CBD beverages, beginning with its
CBD-infused sparkling water brand Quatreau™, across seven states, with
additional states in the months to come. Southern Glazer's will be selling
Quatreau™ through its existing commercial infrastructure, including its
industry-leading Proof® e-commerce platform at sgproof.com. Canopy Growth is
one of the first U.S. CBD beverage producers to access the nationwide network
of a large-scale alcohol distributor to reach consumers across the U.S. at
mainstream retail stores. The agreement also showcases the benefits of the
company's strategic relationship with Constellation Brands, the global beverage
leader.
"This
agreement reinforces our consumer-focused approach to identifying emerging
growth areas where we can add value for our customers," said David
Chaplin, Chief Growth Officer, Southern Glazer's Wine & Spirits.
"There is strong consumer interest in the CBD-infused beverage category
and our distribution network is uniquely positioned to deliver the most
efficient and effective route-to-market for CBD suppliers and retail customers.
We're proud to align with Canopy Growth, a company well-positioned to lead this
product category with a portfolio of premium, highly desirable consumer
brands."
"Innovation
in the beverage industry like we are seeing from Canopy Growth brings new
energy to the marketplace and increases the level of consumer interest in all
our products," added John Wittig, Chief Commercial Officer, Southern
Glazer's Wine & Spirits. "We are excited to be adding Quatreau as the
first CBD-infused beverage in our portfolio."
Quatreau
sparkling water contains 20 mg of premium, U.S. grown hemp-based CBD, in four
refreshing flavors: Cucumber + Mint, Passion Fruit + Guava, Blueberry + Acai,
and Ginger + Lime. With an MSRP of $3.99 per 12-ounce can, Quatreau is a
functional zero-sugar drink that delivers a natural, low calorie beverage
alternative. The stateside launch follows the successful 2020 rollout of
Quatreau in Canada, where it is now the top-selling ready-to-drink CBD
beverage.
Once
again, today’s podcast is sponsored by Phyto
Extractions Inc. (CSE:XTRX), an
agricultural-scale cannabis extraction, distillation and product manufacturer
located in Langley, BC at its co-located Health Canada Licensed Standard
Processing (extraction, no cultivation), Sales (extracts, topicals, and
edibles) through Adastra Labs Inc. and Analytical Testing Laboratory through
Chemia Analytics Inc. Adastra Labs also has a pending Health Canada R&D
license amendment.
Investor
ideas reminds all listeners to read our disclaimers and disclosures on the
Investorideas.com website and that this podcast is not an endorsement to buy
products or services or securities. Investors are reminded all investment
involves risk and possible loss of investment.
Learn
more about our cannabis podcasts at https://www.investorideas.com/Audio/Potcasts.asp
Investors can
trade these stocks and other ideas on our site
using our list of top stock trading
apps including Robinhood , Acorn, Stash and others.
To
hear more Investorideas.com podcasts visit: https://www.investorideas.com/Audio/.
The
Investorideas.com podcasts are also available on iTunes ( Apple Podcasts)
, Audible , Spotify, Tunein, Stitcher,
Spreaker.com, iHeartRadio , Google Play
Music and most audio platforms available.
Potcasts
is now a certified word mark Trademark on the blockchain through Cognate, Inc.
CM Certification-Registration Number: 10468217708
About
Investorideas.com - News that Inspires Big Investing Ideas
Investorideas.com
is a recognized news source publishing third party news, research and original
financial content. Learn about investing in stocks and sector trends with our
news alerts, articles, podcasts and
videos, looking at cannabis, crypto, AI and IoT, mining, sports biotech, water,
renewable energy and more. Investor Idea’s original branded content includes
the following podcasts and columns : Crypto Corner , Play
by Play sports and stock news column, Investor Ideas
Potcasts Cannabis News and Stocks on the Move podcast and
column, Cleantech
and Climate Change , Exploring
Mining the AI
Eye .
Disclaimer/Disclosure: Investorideas.com is a
digital publisher of third party sourced news, articles and equity research as
well as creates original content, including video, interviews and articles.
Original content created by investorideas is protected by copyright laws other
than syndication rights. Our site does not make recommendations for purchases
or sale of stocks, services or products. Nothing on our sites should be
construed as an offer or solicitation to buy or sell products or securities.
All investing involves risk and possible losses. This site is currently
compensated for news publication and distribution, social media and marketing,
content creation and more. Disclosure is posted for each compensated news
release, content published /created if required but otherwise the news was not
compensated for and was published for the sole interest of our readers and
followers. Contact management and IR of
each company directly regarding specific questions. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your news release and our other
news services on the Investorideas.com newswire https://www.investorideas.com/News-Upload/ and tickertagstocknews.com
Global investors must adhere to regulations
of each country. Please read Investorideas.com privacy policy:
https://www.investorideas.com/About/Private_Policy.asp
Investor Ideas does not condone the use of
cannabis except where permissible by law. Our site does not possess,
distribute, or sell cannabis products.
Follow us on Twitter https://twitter.com/Investorideas
Follow
us on Facebook https://www.facebook.com/Investorideas
Follow
us on YouTube https://www.youtube.com/c/Investorideas
Download
our Mobile App for
iPhone and Android
Join
our Investor Club https://www.investorideas.com/membership/
Contact Investorideas.com
800
665 0411
Get more Cannabis Stock Investor Ideas – news, articles, podcasts and stock directory
No comments:
Post a Comment